Dr Helen Coley
Senior Research Fellow in Experimental Cancer Therapeutics
Qualifications: BSc, FIMLS, PhD, MILT
Email: h.coley@surrey.ac.uk
Phone: Work: 01483 68 8617
Room no: 14 AY 04
Office hours
9.00-5.30pm Mon- Fri and by appointment
Further information
Biography
Qualifications
BSc University of Surrey, Biochemistry with Toxicology
FIMLS (Fellow of the Institute of Medical Laboratory Sciences) University of Portsmouth, (Clinical Biochemistry)
PhD University of Cambridge, Clinical Oncology and Radiotherapeutics Unit (CORU), Laboratory of Molecular Biology, Hills Road, Cambridge.
MILT Member of the Institute of Learning and Teaching
Research Interests
Research Background and Interests
The molecular biology of cancer
Disease sites of interest: breast, brain, ovarian and prostate
Anticancer drug resistance
New developmental anticancer agents:
Cytotoxic agents:
Taxane and epothilone compounds
Nanotechnology
Research Collaborations
Collaborations within the University of Surrey:
Ion Beam Centre: Prof Karen Kirkby
Collaborations with the Pharmaceutical Industry:
Astra Zeneca: small molecule receptor tyrosine kinase inhibitors (Iressa, gefitinib)
Bristol Myers Squibb: epothilone B analogue (Ixabepilone)
Cyclacel: cell cycle inhibitory agents (CYC202; seliciclib)
Pharmacia: COX-2 inhibitors (Celebrex; celecoxib)
Novartis
GlaxoSmithKline:
Pfizer: MET (hepatocyte growth factor receptor) small molecule inhibitor (PF2341066)
Teaching
BSc Level 3 Cancer Pathogenesis and Therapeutics (module organiser)
MSc Toxicology (Mutagenesis and Carcinogenesis)


